Background Genetic risk scores (GRS), be it polygenic (PRS) or hazard (PHS), have shown promise to support genetic prediction and clinical trial recruitment for Alzheimer’s disease (AD). A recent study further suggested that sex-matched AD PHS (e.g., male-to-male) outperform sex-mismatched male-to-female), while no benefit was observed PRS. Similar benefits may expected matching by APOE*4 posit...